Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th Edition Staging.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorWisco, Oliver J
Marson, Justin W
Litchman, Graham H
Covington, Kyle R
Martin, Brian J
Quick, Ann P
Siegel, Jennifer J
Caruso, Hillary G
Cook, Robert W
Winkelmann, Richard R
Rigel, Darrell S
Journal titleMelanoma research
Publication Begin page98
Publication End page102
MetadataShow full item record
AbstractCutaneous melanoma (CM) survival is assessed using averaged data from the American Joint Committee on Cancer 8th edition (AJCC8). However, subsets of AJCC8 stages I-III have better or worse survival than the predicted average value. The objective of this study was to determine if the 31-gene expression profile (31-GEP) test for CM can further risk-stratify melanoma-specific mortality within each AJCC8 stage. This retrospective multicenter study of 901 archival CM samples obtained from patients with stages I-III CM assessed 31-GEP test predictions of 5-year melanoma-specific survival (MSS) using Kaplan-Meier and Cox proportional hazards. In stage I-III CM population, patients with a Class 2B result had a lower 5-year MSS (77.8%) than patients with a Class 1A result (98.7%) and log-rank testing demonstrated significant stratification of MSS [χ2 (2df, n = 901) = 99.7, P < 0.001). Within each stage, 31-GEP data provided additional risk stratification, including in stage I [χ2 (2df, n = 415) = 11.3, P = 0.004]. Cox regression multivariable analysis showed that the 31-GEP test was a significant predictor of melanoma-specific mortality (MSM) in patients with stage I-III CM [hazard ratio: 6.44 (95% confidence interval: 2.61-15.85), P < 0.001]. This retrospective study focuses on Class 1A versus Class 2B results. Intermediate results (Class 1B/2A) comprised 21.6% of cases with survival rates between Class 1A and 2B, and similar to 5-year MSS AJCC stage values. Data from the 31-GEP test significantly differentiates MSM into lower (Class 1A) and higher risk (Class 2B) groups within each AJCC8 stage. Incorporating 31-GEP results into AJCC8 survival calculations has the potential to more precisely assess survival and enhance management guidance.
CitationWisco OJ, Marson JW, Litchman GH, Brownstone N, Covington KR, Martin BJ, Quick AP, Siegel JJ, Caruso HG, Cook RW, Winkelmann RR, Rigel DS. Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th Edition Staging. Melanoma Res. 2022 Apr 1;32(2):98-102. doi: 10.1097/CMR.0000000000000804. PMID: 35254332; PMCID: PMC8893124.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
- Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma.
- Authors: Kanaki T, Stang A, Gutzmer R, Zimmer L, Chorti E, Sucker A, Ugurel S, Hadaschik E, Gräger NS, Satzger I, Schadendorf D, Livingstone E
- Issue date: 2019 Sep
- Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study.
- Authors: Dillon LD, McPhee M, Davidson RS, Quick AP, Martin B, Covington KR, Zolochevska O, Cook RW, Vetto JT, Jarell AD, Fleming MD
- Issue date: 2022 Aug
- Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma.
- Authors: Keller J, Schwartz TL, Lizalek JM, Chang ES, Patel AD, Hurley MY, Hsueh EC
- Issue date: 2019 May
- Do Largest Basal Tumor Diameter and the American Joint Committee on Cancer's Cancer Staging Influence Prognostication by Gene Expression Profiling in Choroidal Melanoma.
- Authors: Demirci H, Niziol LM, Ozkurt Z, Slimani N, Ozgonul C, Liu T, Musch DC, Materin M
- Issue date: 2018 Nov
- Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification.
- Authors: Ferris LK, Farberg AS, Middlebrook B, Johnson CE, Lassen N, Oelschlager KM, Maetzold DJ, Cook RW, Rigel DS, Gerami P
- Issue date: 2017 May